Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Sanofi ADR (NASDAQ: SNY) closed at $47.82 down -3.41% from its previous closing price of $49.51. In other words, the price has decreased by -$3.41 from its previous closing price. On the day, 2.97 million shares were traded. SNY stock price reached its highest trading level at $50.09 during the session, while it also had its lowest trading level at $47.57.
Ratios:
For a deeper understanding of Sanofi ADR’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 16.46 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.35. For the most recent quarter (mrq), Quick Ratio is recorded 0.65 and its Current Ratio is at 1.00. In the meantime, Its Debt-to-Equity ratio is 0.33 whereas as Long-Term Debt/Eq ratio is at 0.20.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Argus on July 26, 2024, Reiterated its Buy rating but revised its target price to $60 from $55 previously.
On January 23, 2024, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $55.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SNY now has a Market Capitalization of 125151633408 and an Enterprise Value of 77087383552. As of this moment, Sanofi’s Price-to-Earnings (P/E) ratio for their current fiscal year is 26.36, and their Forward P/E ratio for the next fiscal year is 10.15. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.13. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.51 while its Price-to-Book (P/B) ratio in mrq is 1.54. Its current Enterprise Value per Revenue stands at 1.591 whereas that against EBITDA is 6.166.
Stock Price History:
Over the past 52 weeks, SNY has reached a high of $58.97, while it has fallen to a 52-week low of $45.13. The 50-Day Moving Average of the stock is -12.81%, while the 200-Day Moving Average is calculated to be -5.93%.
Shares Statistics:
For the past three months, SNY has traded an average of 1.76M shares per day and 1861500 over the past ten days. A total of 2.51B shares are outstanding, with a floating share count of 2.51B. Insiders hold about 0.00% of the company’s shares, while institutions hold 11.11% stake in the company. Shares short for SNY as of 1730332800 were 8123732 with a Short Ratio of 4.61, compared to 1727654400 on 9137194. Therefore, it implies a Short% of Shares Outstanding of 8123732 and a Short% of Float of 0.36000002.
Dividends & Splits
The stock’s 5-year Average Dividend Yield is 3.7.
Earnings Estimates
Sanofi ADR (SNY) is currently under the scrutiny of 1.0 analysts, each contributing to the ongoing evaluation of its stock.
Analysts are recommending an EPS of between $4.45 and $4.21 for the fiscal current year, implying an average EPS of $4.36. EPS for the following year is $4.9, with 3.0 analysts recommending between $5.09 and $4.72.
Revenue Estimates
A total of 3 analysts believe the company’s revenue will be $11.52B this quarter.It ranges from a high estimate of $11.69B to a low estimate of $11.42B. As of the current estimate, Sanofi ADR’s year-ago sales were $10.92BFor the next quarter, 3 analysts are estimating revenue of $10.96B. There is a high estimate of $10.96B for the next quarter, whereas the lowest estimate is $10.96B.
A total of 14 analysts have provided revenue estimates for SNY’s current fiscal year. The highest revenue estimate was $48.77B, while the lowest revenue estimate was $44.03B, resulting in an average revenue estimate of $46.34B. In the same quarter a year ago, actual revenue was $43.07BBased on 16 analysts’ estimates, the company’s revenue will be $49.93B in the next fiscal year. The high estimate is $53.55B and the low estimate is $47.32B.
